Jeffrey Landau

Corporate Officer/Principal chez CYTOMX THERAPEUTICS, INC.

Fortune : 188 384 $ au 30/04/2024

46 ans

Health Technology

Consumer Services

Postes actifs de Jeffrey Landau

Sociétés	Poste	Début	Fin
CYTOMX THERAPEUTICS, INC.	Corporate Officer/Principal	01/04/2021	-

Sociétés	Poste	Début	Fin
CATALYST BIOSCIENCES	Corporate Officer/Principal	18/04/2016	01/03/2021
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Sales & Marketing	01/01/2012	-

Virginia Polytechnic Institute & State University	Undergraduate Degree
Stanford Graduate School of Business	Masters Business Admin

Internationale

Etats-Unis

Opérationnelle

Corporate Officer/Principal	2
Undergraduate Degree	1
Masters Business Admin	1

Sectorielle

Health Technology	4
Consumer Services	3

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
CYTOMX THERAPEUTICS, INC.	Health Technology

Entreprise privées	2
Catalyst Biosciences, Inc. Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.	Health Technology
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Health Technology

Entreprise privées

Health Technology